WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 26
19:58 2022
WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
‘WHIM Syndrome Market I
DelveInsight’s ‘WHIM Syndrome Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

DelveInsight’s ‘WHIM Syndrome Market Insights, Epidemiology, and Market Forecast—2032 report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The WHIM Syndrome market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted WHIM Syndrome symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current WHIM Syndrome symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

 

Some of the key facts of the WHIM Syndrome  Market Report:

  • According to Cancer Research UK, in England in 2016 there were 45,960 registrations of newly diagnosed cases of malignant neoplasm of the breast and the directly age-standardized rate per 100,000 population was 169.2 for all cases, and approximately 55,545 cases in the UK

 

 

Key benefits of the Whim Syndrome Market report:

 

“With only symptomatic and no curative therapies approved in any markets, there exists a major unmet need for therapies that target the underlying cause of the disease to address the symptoms of WHIM Syndrome, to treat the patients effectively.”

 

To counter unmet market needs and provide better treatment choices for WHIM Syndrome, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.The major market players in WHIM Syndrome therapeutic market include X4 Pharmaceuticals, among others.

Got queries? Click here to know more about the Whim Syndrome Landscape

Whim Syndrome Market Overview

WHIM syndrome is a primary immunodeficiency disorder, one of a group of disorders characterized by irregularities in the cell development and/or cell maturation process of the immune system. The term WHIM is an acronym for the main signs of the syndrome: warts, hypogammaglobulinemia, infections, and myelokathexis. It is an autosomal-dominant combined immunodeficiency disease caused by mutations in the receptor CXCR4, resulting in increased bone marrow retention and severe reduction in circulating neutrophils.

 

 WHIM Syndrome Diagnosis and Treatment

 

The treatment for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves the exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists. Few major unmet needs in the market include no approved therapies, challenges in current symptomatic treatment options, challenges in hematopoietic stem cell transplantation (HSCT), lack of universal diagnostic criteria, and complicated diagnosis of the condition.

 

Whim Syndrome Market Epidemiological Insight

 

  • According to the National Organization for Rare Disorders (NORD, 2022), WHIM syndrome is an extremely rare disease, with about 100 cases reported in the various medical literature. Another research study states that there are around 105 probable WHIM syndrome patients (searched for diagnosis of myelokathexis or WHIM syndrome or a germline CXCR4 mutation) mined from the various biomedical literature (Heusinkveld et al., 2019).
  • WHIM Syndrome in the United States in 2021, and it is estimated that the prevalence will increase and reach up to 50 males and 75 females by 2032. Among EU5 countries, Germany had the highest number of prevalent cases of WHIM Syndrome (Around 20 cases) in 2021.Japan had about 30 prevalent cases of WHIM Syndrome in 2021. 

Whim Syndrome Market Epidemiological Segmentation 

  • WHIM Syndrome total diagnosed prevalent cases of WHIM Syndrome 
  •  WHIM Syndrome gender-specific cases  

Whim Syndrome Market Outlook 

The report’s WHIM Syndrome market outlook helps to better understand the historic, current, and forecasted WHIM Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of WHIM Syndrome market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the WHIM Syndrome market in 7MM is expected to grow steadily during the study period 2019–2032.

 

The current management options for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves administration of granulocyte-colony stimulating factor (G-CSF), exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.

 

The major market players in WHIM Syndrome therapeutic market are Amgen, Sandoz (Novartis), Pfizer, Takeda, and X4 Pharmaceuticals, among others.

Learn more by requesting for sample @WHIM Syndrome  Market Landscape

WHIM Syndrome Key Companies  

  •  X4 Pharmaceuticals
  •  Plerixafor
  • And others

WHIM Syndrome  Therapies 

  •  Mavorixafor
  •  NIAID
  • And others

Table of Contents

  • Key Insights 
  •  Report Introduction 
  •  Executive Summary of WHIM Syndrome
  • Disease Background and Overview
  • Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  WHIM Syndrome Emerging Therapies
  • WHIM Syndrome Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  WHIM Syndrome  Report Methodology
  •  DelveInsight Capabilities
  • Disclaimer

Click here to read more about WHIM Syndrome Market  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories